Some studies have highlighted an association between Her3 overexpression and metastases in CRC, and Her3 has been identified as a predictive factor for clinical outcome in patients with wild-type KRAS CRC treated with cetuximab.[14–16] However, no consensus has been reached on the association between Her3 expression and CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.